Updated on 4 June 2013
BioSpectrum Asia Top 20 Survey Rank 13 - Sino Biopharmaceutical, China
Sino Biopharmaceutical, an integrated name in R&D, manufacturing and marketing of health enhancing modernized Chinese medicines and chemical medicines, has continued to be a quality oriented enterprise in China. The group has strategically entered into healthcare and hospital business through the acquisition of Chia Tai Shaoyang Orthopedic Hospital.
Sino Biopharmaceutical manufactures therapeutic categories of cardio-cerebral diseases and hepatitis and develops medicines for treating tumors, analgesia, diabetes and respiratory system diseases.
During the year 2012, Sino Biopharmaceutical received 11 clinical approvals and four production approvals, completed clinical research of 57 cases for production approval, which included 10 cardio-cerebral medicines, 16 hepatitis medicines, 13 oncology medicines, four respiratory system medicines, one diabetic medicine and 14 other medicines, which are being developed.
Sino Biopharmecutical is now looking into the development of genetic technology to improve the treatment and prevention of genetic diseases and stimulate the development of biopharmaceutical products. The company is seeking to cooperate with enterprises that possess advanced genetic technology and acquire intellectual proprietary technologies.
Strategically aiming at the international standard, the group's jointly-controlled entity, Beijing Tide Pharmaceutical has received GMP certification for foreign pharmaceutical company from the Public Welfare and Health Ministry of Japan, thus opening window for Japanese pharmaceutical enterprises to invest in the company. The company has also established the Post-Doctoral R&D Institute, the only new hepatitis medicine research center in the country.